Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vulvar Neoplasms 1 Vulvar Diseases 1 Uterine Cervical Dysplasia 1 Papillomavirus Infections 1 Myeloproliferative Disorders 1 Carcinoma in Situ 1

Interventions

fludarabine 19 Whole-Body Irradiation 18 Cyclophosphamide 17 fludarabine phosphate 16 ruxolitinib 15 Mycophenolic Acid 14 Specimen Handling 13 Tacrolimus 11 Azacitidine 11 Biopsy 10 Peripheral Blood Stem Cell Transplantation 9 Melphalan 9 Cytarabine 9 venetoclax 8 Sirolimus 8 Busulfan 8 Stem Cell Transplantation 6 Injections 6 Granulocyte Colony-Stimulating Factor 6 Daunorubicin 5 Cyclosporine 5 CPX-351 5 luspatercept 4 ivosidenib 4 itacitinib 4 fedratinib 4 decitabine and cedazuridine drug combination 4 Thiotepa 4 Liposomes 4 Cyclosporins 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Myeloproliferative Disorders × Hydroxyzine × 1 year × Clear all

NCT03808805 2025-12-03

APHYPAP

University Hospital, Brest

Phase 3 Completed

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡